Institutional Holdings - Affinity Asset Advisors LLC increased its stake in Spyre Therapeutics by 26.0%, owning 606,678 shares valued at $9.08 million after acquiring an additional 125,000 shares [1] - Candriam S.C.A. grew its position by 64.4%, now holding 404,362 shares worth $6.78 million after purchasing 158,332 shares [1] - AlphaQuest LLC raised its stake by 1,485.1%, owning 66,163 shares valued at $1.11 million after acquiring 61,989 shares [1] - Franklin Resources Inc. increased its holdings by 4.6%, now owning 795,275 shares worth $11.91 million after buying 34,647 shares [1] - Intech Investment Management LLC raised its holdings by 22.1%, owning 24,945 shares valued at $373,000 after buying 4,517 shares [1] - Institutional investors and hedge funds collectively own 80.39% of the company's stock [1] Analyst Ratings - Leerink Partners upgraded Spyre Therapeutics to a "strong-buy" rating [2] - Wells Fargo & Company raised the price target from $40.00 to $50.00 and assigned an "overweight" rating [2] - Mizuho also upgraded the stock to a "strong-buy" rating [2] - Citigroup initiated coverage with a "buy" rating and a target price of $64.00 [2] - The average rating for Spyre Therapeutics is "Buy" with a consensus price target of $53.44 [2] Stock Performance - Shares of Spyre Therapeutics opened at $39.89, with a 12-month low of $10.91 and a high of $45.76 [3] - The stock has a market capitalization of $3.13 billion, a P/E ratio of -19.18, and a beta of 3.09 [3] Earnings Report - The company reported earnings of ($0.70) per share, missing the consensus estimate of ($0.66) by ($0.04) [4] - Analysts predict an EPS of -4.46 for the current fiscal year [4] Insider Transactions - CFO Scott L. Burrows sold 2,500 shares at an average price of $40.65, totaling $101,625, reducing ownership by 2.49% [5] - CEO Cameron Turtle sold 15,000 shares at an average price of $42.19, totaling $632,850, reducing ownership by 2.28% [5] - Insiders have sold 47,500 shares worth $1.69 million in the last three months, with insiders owning 15.43% of the stock [5] Company Overview - Spyre Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies for cancer [8] - The company utilizes proprietary protein engineering and biologics design platforms to create targeted molecules aimed at enhancing anti-tumor immune responses [8] - Its preclinical pipeline includes multiple candidate therapies for solid tumor and hematologic oncology indications [8]